Targeted and armed oncolytic poxviruses for cancer: The lead example of JX-594

Current Pharmaceutical Biotechnology

Volumn 13, Issue 9, 2012, Pages 1768-1772

  Breitbach, Caroline J ^a   Thorne, Steve H ^b   Bell, John C ^a,c,d   Kirn, David H ^a  

^a Jennerex Inc   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

JX 594; Oncolytic poxvirus

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; JX 594; JX 929; ONCOLYTIC POXVIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ANTINEOPLASTIC ACTIVITY; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; FLU LIKE SYNDROME; GENE EXPRESSION; GENETIC ENGINEERING; HUMAN; HYPERBILIRUBINEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; METASTASIS; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POXVIRUS; REVIEW; THROMBOCYTOPENIA; TRANSGENE; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

POXVIRIDAE; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 84863553090     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800958922     Document Type: Review

References (64)

1. Moss, B. Poxviridae: The viruses and their replication. In: Field's Virology, 4th ed.; D.M. K.; Fields, B.N.; Howley, P.M. Eds. Lippincott-Raven: Philadelphia, 2001, p Ch84.
2. Buller, R.M.; Palumbo, G.J. Poxvirus pathogenesis. Microbiol. Rev., 1991, 55(1), 80-122.
3. Fenner, F.; Henderson, D.A.; Arita, I.; Jezek, Z.; Ladnyi, I.D. Smallpox and its eradication. World Health Organization: Geneva, 1988.
4. Enserink, M. Bioterrorism. In search of a kinder, gentler vaccine. Science, 2002, 296(5573), 1594.
5. Cono, J.; Casey, C.G.; Bell, D.M. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm. Rep., 2003, 52(RR-4), 1-28.
6. Wittek, R. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int. J. Infect. Dis., 2006, 10(3), 193-201.
7. De Clercq, E. Cidofovir in the treatment of poxvirus infections. Antiviral. Res., 2002, 55(1), 1-13.
8. Yang, G.; Pevear, D.C.; Davies, M.H.; Collett, M.S.; Bailey, T.; Rippen, S.; Barone, L.; Burns, C.; Rhodes, G.; Tohan, S.; Huggins, J.W.; Baker, R.O.; Buller, R.L.; Touchette, E.; Waller, K.; Schriewer, J.; Neyts, J.; DeClercq, E.; Jones, K.; Hruby, D.; Jordan, R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J. Virol., 2005, 79(20), 13139-13149.
9. Reeves, P.M.; Bommarius, B.; Lebeis, S.; McNulty, S.; Christensen, J.; Swimm, A.; Chahroudi, A.; Chavan, R.; Feinberg, M.B.; Veach, D.; Bornmann, W.; Sherman, M.; Kalman, D. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med., 2005, 11(7), 731-739.
10. Miller, J.D.; van der Most, R.G.; Akondy, R.S.; Glidewell, J.T.; Albott, S.; Masopust, D.; Murali-Krishna, K.; Mahar, P.L.; Edupuganti, S.; Lalor, S.; Germon, S.; Del Rio, C.; Mulligan, M.J.; Staprans, S.I.; Altman, J.D.; Feinberg, M.B.; Ahmed, R. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity, 2008, 28(5), 710-722.
11. Putz, M.M.; Midgley, C.M.; Law, M.; Smith, G.L. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat. Med., 2006, 12(11), 1310-1315.
12. Graham, B.S.; Gorse, G.J.; Schwartz, D.H.; Keefer, M.C.; McElrath, M.J.; Matthews, T.J.; Wright, P.F.; Belshe, R.B.; Clements, M.L.; Dolin, R. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. J. Infect. Dis., 1994, 170(4), 782-786.
13. Kanesa-thasan, N.; Smucny, J.J.; Hoke, C.H.; Marks, D.H.; Konishi, E.; Kurane, I.; Tang, D.B.; Vaughn, D.W.; Mason, P.W.; Shope, R. E. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-- poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine, 2000, 19(4-5), 483-491.
14. McClain, D.J.; Summers, P.L.; Harrison, S.A.; Schmaljohn, A.L.; Schmaljohn, C.S. Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J. Med. Virol., 2000, 60(1), 77-85.
15. Cadoz, M.; Strady, A.; Meignier, B.; Taylor, J.; Tartaglia, J.; Paoletti, E.; Plotkin, S. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet, 1992, 339(8807), 1429-1432.
16. Ockenhouse, C.F.; Sun, P.F.; Lanar, D.E.; Wellde, B.T.; Hall, B. T.; Kester, K.; Stoute, J.A.; Magill, A.; Krzych, U.; Farley, L.; Wirtz, R.A.; Sadoff, J.C.; Kaslow, D.C.; Kumar, S.; Church, L.W.; Crutcher, J.M.; Wizel, B.; Hoffman, S.; Lalvani, A.; Hill, A.V.; Tine, J.A.; Guito, K.P.; de Taisne, C.; Anders, R.; Ballou, W.R.; et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a poxvectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis., 1998, 177(6), 1664-1673.
17. Doehn, C.; Kausch, I.; Bohmer, T.; Sommerauer, M.; Jocham, D. Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine. Curr. Opin. Mol. Ther., 2007, 9(2), 183-189.
18. Rochlitz, C.; Figlin, R.; Squiban, P.; Salzberg, M.; Pless, M.; Herrmann, R.; Tartour, E.; Zhao, Y.; Bizouarne, N.; Baudin, M.; Acres, B. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene. Med., 2003, 5(8), 690-699.
19. Jager, E.; Karbach, J.; Gnjatic, S.; Neumann, A.; Bender, A.; Valmori, D.; Ayyoub, M.; Ritter, E.; Ritter, G.; Jager, D.; Panicali, D.; Hoffman, E.; Pan, L.; Oettgen, H.; Old, L. J.; Knuth, A. Recombinant vaccinia/ fowlpox NY-ESO-1 vaccines induce both humoral and cellular NYESO- 1-specific immune responses in cancer patients. Proc. Natl. Acad. Sci. USA, 2006, 103(39), 14453-14458.
20. Gulley, J.L.; Arlen, P.M.; Tsang, K.Y.; Yokokawa, J.; Palena, C.; Poole, D.J.; Remondo, C.; Cereda, V.; Jones, J.L.; Pazdur, M.P.; Higgins, J.P.; Hodge, J.W.; Steinberg, S.M.; Kotz, H.; Dahut, W. L.; Schlom, J. Pilot study of vaccination with recombinant CEAMUC- 1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res., 2008, 14(10), 3060-3069.
21. Kirn, D.H.; Thorne, S.H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer, 2009, 9(1), 64-71.
22. Doceul, V.; Hollinshead, M.; van der Linden, L.; Smith, G.L. Repulsion of superinfecting virions: a mechanism for rapid virus spread. Science, 2010, 327(5967), 873-876.
23. Wein, L.M.; Wu, J.T.; Kirn, D.H. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res., 2003, 63(6), 1317-1324.
24. Roberts, K.L.; Smith, G.L. Vaccinia virus morphogenesis and dissemination. Trends Microbiol., 2008, 16(10), 472-479.
25. Thorne, S.H.; Hwang, T.H.; O'Gorman, W.E.; Bartlett, D.L.; Sei, S.; Kanji, F.; Brown, C.; Werier, J.; Cho, J.H.; Lee, D.E.; Wang, Y.; Bell, J.; Kirn, D.H. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest., 2007, 117(11), 3350-3358.
26. Mercer, J.; Helenius, A. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science, 2008, 320(5875), 531-535.
27. Moss, B. Poxvirus entry and membrane fusion. Virology, 2006, 344(1), 48-54.
28. Vanderplasschen, A.; Mathew, E.; Hollinshead, M.; Sim, R.B.; Smith, G.L. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl. Acad. Sci. USA, 1998, 95(13), 7544-7549.
29. Bell, E.; Shamim, M.; Whitbeck, J.C.; Sfyroera, G.; Lambris, J.D.; Isaacs, S. N. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology, 2004, 325(2), 425-431.
30. McCart, J.A.; Ward, J.M.; Lee, J.; Hu, Y.; Alexander, H.R.; Libutti, S.K.; Moss, B.; Bartlett, D.L. Systemic cancer therapy with a tumorselective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res., 2001, 61(24), 8751-8757.
31. Kirn, D.H.; Wang, Y.; Liang, W.; Contag, C.H.; Thorne, S.H. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res., 2008, 68(7), 2071-2075.
32. Wang, F.; Ma, Y.; Barrett, J. W.; Gao, X.; Loh, J.; Barton, E.; Virgin, H. W.; McFadden, G. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat. Immunol., 2004, 5(12), 1266-1274.
33. Yu, Y.A.; Shabahang, S.; Timiryasova, T.M.; Zhang, Q.; Beltz, R.; Gentschev, I.; Goebel, W.; Szalay, A. A. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat. Biotechnol., 2004, 22(3), 313-320.
34. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70.
35. Katsafanas, G.C.; Moss, B. Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/ proliferation-associated protein (p137) individually or as a heterodimer. J. Biol. Chem., 2004, 279(50), 52210-522107.
36. Yang, H.; Kim, S.K.; Kim, M.; Reche, P.A.; Morehead, T.J.; Damon, I.K.; Welsh, R.M.; Reinherz, E.L. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest., 2005, 115 (2), 379-387.
37. Gnant, M.F.; Noll, L.A.; Irvine, K.R.; Puhlmann, M.; Terrill, R.E.; Alexander, H.R. Jr.; Bartlett, D.L. Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases. J.Natl. Cancer Inst., 1999, 91(20), 1744-1750.
38. Buller, R.M.; Smith, G.L.; Cremer, K.; Notkins, A.L.; Moss, B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature, 1985, 317(6040), 813-815.
39. Kim, J.H.; Oh, J.Y.; Park, B.H.; Lee, D.E.; Kim, J.S.; Park, H.E.; Roh, M.S.; Je, J.E.; Yoon, J.H.; Thorne, S.H.; Kirn, D.; Hwang, T.H. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol. Ther., 2006, 14(3), 361-370.
40. Hengstschlager, M.; Knofler, M.; Mullner, E.W.; Ogris, E.; Wintersberger, E.; Wawra, E. Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virustransformed cells. J. Biol. Chem., 1994, 269(19), 13836-13842.
41. Colamonici, O.R.; Domanski, P.; Sweitzer, S.M.; Larner, A.; Buller, R.M. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J. Biol. Chem., 1995, 270(27), 15974-15978.
42. Symons, J.A.; Alcami, A.; Smith, G.L. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell, 1995, 81(4), 551-560.
43. Kirn, D.H.; Wang, Y.; Le Boeuf, F.; Bell, J.; Thorne, S.H. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med., 2007, 4(12), e353.
44. Alcami, A.; Symons, J.A.; Smith, G.L. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J. Virol., 2000, 74(23), 11230-11239.
45. Clarke, M.F.; Becker, M.W. Stem cells: The real culprits in cancer? Sci. Am., 2006, 295(1), 52-59.
46. Clarke, M. F.; Fuller, M. Stem cells and cancer: two faces of eve. Cell, 2006, 124(6), 1111-1115.
47. Lotze, M.T.; Tracey, K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol., 2005, 5(4), 331-342.
48. Rubartelli, A.; Lotze, M.T. Inside, outside, upside down: damageassociated molecular-pattern molecules (DAMPs) and redox. Trends Immunol., 2007, 28(10), 429-436.
49. Zhu, J.; Martinez, J.; Huang, X.; Yang, Y. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood, 2007, 109(2), 619-625.
50. Thorne, S.H.; Hwang, T.H.; O'Gorman, W.E.; Bartlett, D.L.; Sei, S.; Kanji, F.; Brown, C.; Werier, J.; Cho, J.H.; Lee, D.E.; Wang, Y.; Bell, J.; Kirn, D.H. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest., 2007, 117(11), 3350-3358.
51. Breitbach, C.J.; Paterson, J.M.; Lemay, C.G.; Falls, T.J.; McGuire, A.; Parato, K.A.; Stojdl, D.F.; Daneshmand, M.; Speth, K.; Kirn, D.; McCart, J.A.; Atkins, H.; Bell, J.C. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther., 2007, 15(9), 1686-1693.
52. Liu, T.C.; Hwang, T.; Park, B.H.; Bell, J.; Kirn, D.H. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol. Ther., 2008, 16(9), 1637-1642.
53. Hida, K.; Hida, Y.; Amin, D.N.; Flint, A.F.; Panigrahy, D.; Morton, C.C.; Klagsbrun, M. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res., 2004, 64(22), 8249-8255.
54. Park, B.H.; Hwang, T.; Liu, T.C.; Sze, D.Y.; Kim, J.S.; Kwon, H. C.; Oh, S.Y.; Han, S.Y.; Yoon, J.H.; Hong, S.H.; Moon, A.; Speth, K.; Park, C.; Ahn, Y. J.; Daneshmand, M.; Rhee, B. G.; Pinedo, H. M.; Bell, J.C.; Kirn, D.H. Use of a targeted oncolytic poxvirus, JX- 594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol., 2008, 9(6), 533-542.
55. Smith, G. L.; Moss, B. Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene, 1983, 25(1), 21-28.
56. Chakrabarti, S.; Sisler, J. R.; Moss, B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques, 1997, 23(6), 1094-1097.
57. Davison, A.J.; Moss, B. Structure of vaccinia virus late promoters. J. Mol. Biol., 1989, 210(4), 771-784.
58. Bronte, V.; Caroll, M.W.; Goletz, T.I.; Weng, M., Overwijk, W.W.; Marincola, F.; Rosenberg, S.A. Moss, B.; Restigo, N.P. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine PNAS, 1997, 94, 3183-3188.
59. Halsell, J.S.; Riddle, J.R.; Atwood, J.E.; Gardner, P.; Shope, R.; Poland, G.A.; Gray, G. C.; Ostroff, S.; Eckart, R.E.; Hospenthal, D. R.; Gibson, R.L.; Grabenstein, J. D.; Arness, M. K.; Tornberg, D.N. Myopericarditis following smallpox vaccination among vaccinianaive US military personnel. JAMA, 2003, 289(24), 3283-3289.
60. Mastrangelo, M.J.; Maguire, H.C. Jr.; Eisenlohr, L.C.; Laughlin, C.E.; Monken, C.E.; McCue, P.A.; Kovatich, A.J.; Lattime, E.C. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene. Ther., 1999, 6(5), 409-422.
61. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; Rubinstein, L.; Verweij, J.; Van Glabbeke, M.; van Oosterom, A. T.; Christian, M. C.; Gwyther, S. G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst., 2000, 92(3), 205-216.
62. Choi, H.; Charnsangavej, C.; de Castro Faria, S.; Tamm, E.P.; Benjamin, R.S.; Johnson, M.M.; Macapinlac, H.A.; Podoloff, D.A. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am. J. Roentgenol., 2004, 183(6), 1619-1628.
63. Choi, H.; Charnsangavej, C.; Faria, S.C.; Macapinlac, H.A.; Burgess, M.A.; Patel, S.R.; Chen, L.L.; Podoloff, D.A.; Benjamin, R.S. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol., 2007, 25(13), 1753-1759.
64. Burke, J.S.J. Chow, L. Jonker, D. Haas, A. Nieva, J. Sabourin, K. Pelusio, A. Breitbach, C. Hwang, T. Moon, A. Parato, K. Daneshmand, M. Bell, J.C. Kirn, D.H. Demonstration of Delivery and Antitumoral Activity of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, Following a Single Intravenous Infusion in Patients with Refractory Metastatic Cancers. In: American Society of Gene & Cell Therapy 13th Annual Meeting, Molecular Therapy: Washington D.C. 2010; Vol. 18 S. 1, p S14.